Skip to Main Content

Advertisement

Skip Nav Destination

Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study.

Cancer Res (2009) 69 (2_Supplement): 80.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Valentina Guarneri
  • PierFranco Conte
The Oncologist (2009) 14 (7): 645.
Close Modal

or Create an Account

Close Modal
Close Modal